title: Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients.
abstract: BACKGROUND
  The incidence of hypersensitivity reactions during anesthesia is underestimated because clinical symptoms may vary and diagnosis is not obvious. Our aim was to investigate the consequences of a systematic follow-up of patients on the estimated incidence of allergic reactions during anesthesia.
  
  
  METHODS
  We conducted a prospective study over a 2-year period (70,000 anesthesias). When patients were suspected with hypersensitivity reactions or with unexplained adverse reactions during anesthesia, blood was sampled to measure histamine and tryptase, and then skin tests were performed 4-6 weeks later.
  
  
  RESULTS
  During the studied period, 39 patients were enrolled in the database. Eight were excluded because of lack of skin tests. Twenty-two patients had clinical features compatible with immediate hypersensitivity reaction, and nine had reactions rated as 'unexplained' by the attending physician. Following systematic investigation, we found 22 hypersensitivity reactions (15 patients with obvious and seven with unexplained reactions) during anesthesia. This increases the estimated incidence of hypersensitivity reactions from 1 : 4667 to 1 : 3180 anesthesias. Tryptase concentrations were increased in only 50% of these patients. In our series, positive and negative predictive values of tryptase at T(0) for the diagnosis of anaphylaxis were 100% and 60%, respectively. Latex was the major causative agent, followed by neuromuscular blocking agents and antibiotics.
  
  
  CONCLUSIONS
  Systematic follow-up of patients with unexplained reactions during anesthesia increases the estimated incidence of IgE-mediated hypersensitivity reactions during anesthesia by 50%.
authors.affiliation: Departments of Anesthesia and Intensive Care, Hôtel-Dieu, Nantes, France. jmmalinovsky@chu-reims.fr
authors.forename: J-M
authors.initials: JM
authors.lastname: Malinovsky
authors.forename: S
authors.initials: S
authors.lastname: Decagny
authors.forename: F
authors.initials: F
authors.lastname: Wessel
authors.forename: L
authors.initials: L
authors.lastname: Guilloux
authors.forename: P M
authors.initials: PM
authors.lastname: Mertes
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology*; D000758:Anesthesia / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006632:Histamine / Q000097:blood; D006801:Humans; D015994:Incidence; D007840:Latex / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D012882:Skin Tests / Q000706:statistics & numerical data; D053802:Tryptases / Q000097:blood
chemical_list: D000900:Anti-Bacterial Agents; D007840:Latex; D009466:Neuromuscular Blocking Agents; D006632:Histamine; D053802:Tryptases